Kneat.com (KSI) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Annual recurring revenue (ARR) rose 60% year-over-year to CAD 45.4 million in Q2 2024, with SaaS license fee revenue up 54% to CAD 10.8 million and total revenue up 45% to CAD 11.7 million compared to Q2 2023.
Gross margin improved to 74% in Q2 2024 from 66% in Q2 2023.
Net loss narrowed to $3.1 million in Q2 2024 from $5.4 million in Q2 2023.
Growth was driven primarily by expansions within existing customers, with new customer additions and a balanced geographic split between the U.S. and Europe.
Launched Kneat Gx 9.2 and signed a strategic partnership with Körber in Q2 2024.
Financial highlights
Q2 2024 total revenue: $11.7 million (+45% year-over-year); SaaS revenue: $10.8 million (+54%).
Q2 2024 gross profit: $8.7 million (+63% year-over-year); gross margin: 74% (vs. 66%).
Q2 2024 EBITDA: $0.5 million (vs. -$3.5 million); Adjusted EBITDA: $1.6 million (vs. -$1.3 million).
SaaS license revenue for the first half of 2024 grew 53% year-over-year to CAD 20.6 million, outpacing overall revenue growth.
Professional services revenue was CAD 0.8 million, lower than the prior year as partners take on more services.
Outlook and guidance
Management expects continued business momentum and growth in 2024, focusing on scaling with new users, customers, and features.
No specific quantitative guidance was provided, but the company anticipates further growth in ARR and SaaS revenue, with partners playing an increasing role.
Latest events from Kneat.com
- Software revenue up 33% in 2025; ARR at $74.1m; targeting cash flow breakeven in 2026.KSI
Q4 202526 Feb 2026 - SaaS validation platform achieves 138% net revenue retention and targets $2B+ ARR in life sciences.KSI
Small-Cap Growth Virtual Investor Conference 20243 Feb 2026 - Aggressive drilling at Coyote begins soon, targeting high-grade uranium in a fully funded campaign.KSI
Emerging Growth Conference 8921 Jan 2026 - Digitized validation leader achieves rapid ARR growth and major efficiency gains for life sciences.KSI
Investor presentation21 Jan 2026 - Record Q3 revenue, ARR, and margin growth, with new global contracts and strong outlook.KSI
Q3 202415 Jan 2026 - High-growth validation software leader drives digital transformation in life sciences.KSI
Planet MicroCap Showcase: VEGAS 202527 Dec 2025 - Record SaaS-driven growth, high margins, and strong cash position support 2025 momentum.KSI
Q4 202416 Dec 2025 - ARR up 51%, revenue up 37%, and profitability improved in Q1 2025.KSI
Q1 202524 Nov 2025 - Q2 revenue up 32%, ARR up 43%, with record SaaS growth and strong outlook for 2026.KSI
Q2 202523 Nov 2025